Bremelanotide

What it is

Bremelanotide (PT-141) is a synthetic cyclic heptapeptide that functions as a non-selective melanocortin receptor agonist with primary activity at the MC3R and MC4R subtypes. It was originally developed by Palatin Technologies as a derivative of melanotan-II, with structural modifications to the parent compound.

The brand-name bremelanotide product Vyleesi received FDA approval in June 2019 for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). This was a notable approval — sexual desire disorders had limited pharmaceutical options, and Vyleesi represented a mechanistically novel approach acting on central pathways rather than peripheral mechanisms (the latter being how PDE5 inhibitors like sildenafil work for erectile dysfunction).

Vyleesi is FDA-approved only for premenopausal women with acquired, generalized HSDD; use in men or in postmenopausal women is off-label, and benefit in these groups has not been established. Your provider may also prescribe compounded bremelanotide from a licensed pharmacy. Compounded medications are not FDA-approved; the FDA does not review them for safety, effectiveness, or quality, and compounded bremelanotide is not a generic version of Vyleesi.

Mechanism of action

Unlike PDE5 inhibitors, which act on peripheral vascular smooth muscle to support penile erection, bremelanotide acts on central nervous system pathways involved in sexual desire and arousal:

• MC3R/MC4R activation in hypothalamus: activation of these melanocortin receptors in the hypothalamic paraventricular nucleus and other regions modulates sexual response circuits, increasing sexual desire and central arousal.
• Dopaminergic modulation: melanocortin signaling in these circuits influences mesolimbic dopamine pathways involved in motivation and reward — the neurochemistry of desire.
• Distinct from peripheral vascular effects: bremelanotide does not significantly affect peripheral blood flow or vascular smooth muscle tone in the way PDE5 inhibitors do.
• Female sexual response: in women, the central mechanism produces effects on subjective desire and arousal without requiring genital vascular changes.
• Half-life: approximately 2.7 hours, which supports the as-needed (rather than daily) dosing pattern.

Research findings

RECONNECT trials (the basis for Vyleesi’s FDA approval): two Phase III trials in premenopausal women with HSDD demonstrated statistically significant improvements in sexual desire scores and reductions in distress related to low desire compared to placebo. Effect sizes were modest but meaningful, and the trials supported Vyleesi’s FDA approval.

Off-label use: bremelanotide has been studied in men and in postmenopausal women. These uses are off-label, and benefit in these groups has not been established.

Comparison to other approaches: bremelanotide acts through a distinct mechanism from PDE5 inhibitors, hormonal interventions (testosterone), and behavioral therapy.

Side effects and contraindications

Side effects of bremelanotide can be significant:

• Nausea: the most common side effect, occurring in approximately 40% of patients in trials. Often severe enough to limit continued use in some patients.
• Flushing and sweating
• Headache
• Transient blood pressure elevation: blood pressure increases of approximately 6 mmHg systolic and 3 mmHg diastolic occur within 2–4 hours of dosing. Blood pressure should be checked beforehand, and use is avoided in uncontrolled hypertension.
• Heart rate decrease: mild bradycardia in some patients
• Focal hyperpigmentation: can occur with repeated use due to MC1R cross-activation. Reversible upon discontinuation.
• Injection site reactions

Contraindicated in:

• Uncontrolled hypertension or known cardiovascular disease
• Pregnancy and breastfeeding
• Use with naltrexone or other opioid antagonists (reduces effectiveness)
• History of severe melanoma (MC1R activation is theoretically concerning, though clinical relevance is debated)

What we don’t yet know

Long-term effects of regular use over years are not well characterized — Vyleesi has been on the market only since 2019. Optimal patient selection criteria for maximum benefit and tolerability are still being refined. The relative role of bremelanotide vs. other interventions for low sexual desire (psychosexual therapy, hormonal therapy, behavioral approaches) is not well established in comparative studies. The mechanisms underlying individual variability in response are not fully characterized.